ValTech Lifesciences is developing the next-gen heart valve designs to improve the hemodynamic performance of existing devices.
Total raised: $176.46K
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.09.2024 | - | $176.46K | - |
Mentions in press and media 4
| Date | Title | Description |
| 27.09.2024 | EGYM secures $200M, Mubadala acquires stake in Revolut, and the Hungarian tech surge | This week we tracked more than 90 tech funding deals worth over €1.3 billion, and over 5 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most im... |
| 23.09.2024 | ValTech Lifesciences: Pioneering the Future of Heart Valve Technology | In a world where heart disease looms large, innovation is the lifeline. Valvular heart disease impacts over 70 million people globally. As age creeps in, so does the risk. For many, the solution lies in prosthetic heart valves. Yet, these s... |
| 23.09.2024 | ValTech Lifesciences receives the CHF 150,000 Kick to bring the next-generation prosthetic heart valves to patients | Valvular heart disease affects over 70 million individuals worldwide, with its prevalence increasing with age. Patients who undergo prosthetic heart valve implantation face significant challenges, including limited valve durability and the ... |
| 23.09.2024 | ValTech Lifesciences receives CHF 150,000 to advance prosthetic heart valves | Valvular heart disease affects over 70 million individuals worldwide, with its prevalence increasing with age. Patients who undergo prosthetic heart valve implantation face significant challenges, including limited valve durability and the... |